At a glance
- Originator Merck & Co
- Class Antiallergics; Antiasthmatics; Bronchodilators
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias; Asthma
Most Recent Events
- 25 Jun 1998 No-Development-Reported for Asthma in USA (Inhalation)
- 23 Apr 1997 No-Development-Reported for Arrhythmias in USA (Unknown route)
- 14 Oct 1994 Preclinical development for Arrhythmias in USA (Unknown route)